

DAFTAR PUSTAKA

- Aditiyono (2018). CA 125 and Risk of Malignacy Index (RMI)2 AS Epithelial Malignacy Ovarium Predictor. *Mandala Heal. A Sci. J.* 11 : 18–30.
- Anonim (2022). Registrasi Kanker Berbasis Rumah Sakit, Tim Registrasi kanker RSUP Dr. Sardjito Yogyakarta [WWW Document]. *Canreg.fkkmk (2022). No Title [WWW Doc. 1 April 2022, 21.05.* URL <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/>
- Anonim (2021). Albumin Generation 2 Order information fro Cobas, Roche Diagnostics, Sandhofer Strasse 116.
- Anonim (2020). Elecsys® CA 125 II Inserkit Cobas, Cobas E, Elecsys and Precicontrol are trademarks of Roche. Intralipid is a trademark of Fresenius Kabi AB.
- Anonim (2015). External Quality Assurance Services EQAS ® Program User Guide, Laboratories BioRad 1–137.
- Aqilla S, Harsono, A.B., & Agustina, H. (2022). Gambaran Klinis dan Histopatologi Kanker Ovarium di RSUP Dr. Hasan Sadikin Bandung Tahun 2019-2020. *Indones. J. Obstet. Gynecol. Sci.* 5 : 127–135.
- Asher, V., Lee, J., & Bali, A. (2012). Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. *Med. Oncol.* 29 : 2005–2009.
- Bekos, C., Grimm, C., Gensthaler, L., Bartl, T., Reinthaller, A., Schwameis, R., *et al.* (2022). The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate. *Geburtshilfe Frauenheilkd.* 82 : 59–67.
- Benedet, J.L., Bender, H., & Pecorelli, S. (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. *Int. J. Gynecol. Obstet.* 70 : 209–262.
- Berek, J.S., Kehoe, S.T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary , fallopian tube , and peritoneum. *Int J Gynecol Obs.* 143 : 59–78.
- Biswas, S.S., Bindra, M., Jain, V., & Gokhale, P. (2015). Evaluation of Imprecision, Bias and Total Error of Clinical Chemistry Analysers. *Indian J. Clin. Biochem.* 30 : 104–108.
- Boiero, C., Allemandi, D., Longhi, M., & Llabot, J.M. (2015). RP-HPLC method development for the simultaneous determination of timolol maleate and human serum albumin in albumin nanoparticles. *J. Pharm. Biomed. Anal.* 111 : 186–189.
- Brady, P. (2020). CA125 and Ca Ovarium, Comprehensive review. *Shipp. World Shipbuild.* 208 : 46–48.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., *et al.* (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 74 : 229–263.
- Budiana, B., Mahendra, B., Putra, M., Wijaya, H., Putra, A., & Karisma, N. (2023). Accuracy of Cancer Antigen 125 and Albumin Before Operation To Predict

- the Operation Outcome in Patients With Advanced Stage Epithelial Type Ovarian Cancer. *J. Heal. Sains* 4 : 143–154.
- Budiana, I.N.G., Angelina, M., & Pemayun, T.G.A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J. Turkish-German Gynecol. Assoc.* 20 : 47–54.
- Cao, Y., Ni, X., Wang, Y., Wang, L., Yuan, K., Gan, G., *et al.* (2019). Clinical and prognostic significance of combined plasma fibrinogen concentrations and the monocyte-to-lymphocyte ratio in patients with ovarian cancer. *Ann. Transl. Med.* 7 : 242–242.
- Chen, W., Zhong, S., Shan, B., Zhou, S., Wu, X., Yang, H., *et al.* (2020). Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. *J. Ovarian Res.* 13 : 89.
- Christina, I.M., Philipp, F., Hauptmann, S., Sehouli, J., Mucinous, E.Á., & Clear, Á. (2016). The new WHO classification of ovarian , fallopian tube , and primary peritoneal cancer and its clinical implications. *Arch. Gynecol. Obstet.* 293 : 695–700.
- Cybula, M., & Bieniasz, M. (2022). Review Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates. *Oncotarget* 13 : 553–575.
- Dai, D., Balega, J., Sundar, S., Kehoe, S., Elattar, A., Phillips, A., *et al.* (2022). Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study. *J. Investig. Surg.* 35 : 426–431.
- Gaudette, C., & Boynton, D. (1995). Characterization from Ovarian of an Ovarian Cancer Patients ' Cancer Activating Factor in Ascites. *Clin. Cancer Res.* 1 : 1223–1232.
- Ge, L. and F. wang (2018). Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients : a systematic review and dose – response meta- analysis of observational studies. *Cancer Manag. Res.* 10 : 815–825.
- Gupta, D., & Lis, C.G. (2009). Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. *J. Ovarian Res.* 2 : 1–20.
- Hirst, J., Crow, J., Godwin, A., Hirst, J., Crow, J., & Godwin, A. (2018). Ovarian Cancer Genetics : Subtypes and Risk Factors Ovarian Cancer Genetics : Subtypes and Risk Factors. *intechopen* 3–38.
- Kandukuri, S.R., & Rao, J. (2015). Opinion FIGO 2013 staging system for ovarian cancer : what is new in comparison to the 1988 staging system. *Gynecol. cancer* 27 : 48–52.
- Kehoe, S., Kehoe, S., & Kehoe, S. (2020). FIGO staging in ovarian carcinoma and histological subtypes. *J Gynecol Oncol* 31 : 6–8.
- Kopuz, A., Training, T., Toz, E., Training, T., Turan, V., Training, T., *et al.* (2014). The Relationship Between Tumor Markers And Albumin With The Ascites Existence In Malign Epithelial Ovarian Tumor. *Indian J. Med. Res. Pharm. Sci.* 1 : 27–31.
- Kumar, A., Torres, M.L., Cliby, W.A., Kalli, K.R., Bogani, G., Aletti, G., *et al.* (2017). Inflammatory and nutritional serum markers as predictors of peri-operative morbidity and survival in ovarian cancer. *Anticancer Res.* 37 : 3673–

3677.

- Kurman, R.J., & Shih, I.M. (2016). The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. *Am. J. Pathol.* 186 : 733–747.
- Liao, X.Y., Huang, G.J., Gao, C., & Wang, G.H. (2014). A meta-analysis of serum cancer antigen 125 array for diagnosis of ovarian cancer in Chinese. *J. Cancer Res. Ther.* 10 : C222–C224.
- Ma, R., Okugawa, Y., Shimura, T., Yamashita, S., Sato, Y., Yin, C., *et al.* (2024). Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer. *Surg. Oncol.* 53 : 1–6.
- Matte, I., Garde-granger, P., Bessette, P., & Piché, A. (2019). Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. *BMC Cancer* 19 : 1–14.
- Matz, M., Coleman, M.P., Sant, M., Dolores, M., Visser, O., Gore, M., *et al.* (2017). Gynecologic Oncology The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol. Oncol.* 144 : 405–413.
- Mehra, P., Aditi, S., Prasad, K.M., & Bariar, N.K. (2023). Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors : A Distribution Pattern in a Tertiary Care Center. *Cureus* 15 : 1–10.
- Mulawardhana, P., Hartono, P., Nugroho, H., & Ayuningtyas, A. (2021). Death of 43 Indonesian women with ovarian cancer: A case series. *Int. J. Surg. Case Rep.* 78 : 391–396.
- Nazha, B. (2015). Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? *World J. Gastrointest. Surg.* 7 : 370.
- Ovarian, C., Be, C., Early, F., Stages, O.C., Should, W., Ask, Y., *et al.* (2018). Ovarian Cancer Early Detection , Diagnosis , and Staging Can Ovarian Cancer Be Found Early. *Am. Cancer Soc.* 1–25.
- Parker, D., Bradley, C., Bogle, S.M., Lay, J., Masood, M., Hancock, A.K., *et al.* (1994). Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. *BJOG An Int. J. Obstet. Gynaecol.* 101 : 888–893.
- Rifai, N., W.K, R., Young, I., Burnam, F.C.-A.D., & Wittwer, C.T. (2018). TIETZ TEXTBOOK OF LABORATORY MEDICINE SEVENTH EDITION.
- Rojas, V., Hirshfield, K.M., Ganesan, S., & Rodriguez-rodriguez, L. (2016). Molecular Characterization of Epithelial Ovarian Cancer : Implications for Diagnosis and Treatment. *Int. J. Mol. Sci.* 17 : 1–23.
- Schober, P., & Schwarte, L.A. (2018). Correlation coefficients: Appropriate use and interpretation. *Anesth. Analg.* 126 : 1763–1768.
- Schwartz, G.G., Tretli, S., Klug, M.G., Robsahm, T.E., & Forks, G. (2020). Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort. *Gynecol Oncol* 159 : 264–269.
- Soeters, P.B., Wolfe, R.R., & Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and Clinical Significance. *J. Parenter. Enter. Nutr.* 43 : 181–193.



- Song, Y., Yuan, M., Wang, G., & Group, F. (2023). Expert Opinion on Therapeutic Targets Update value and clinical application of MUC16 (cancer antigen 125). *Expert Opin. Ther. Targets* 27 : 745–756.
- Tang, Y., Liu, Y., Xia, Y., Zhao, F., & Zeng, B. (2023). Simultaneous Detection of Ovarian Cancer-Concerned HE4 and CA125 Markers Based on Cu Single-Atom-Triggered CdSQDs and Eu MOF@IsoluminolECL. *Anal. Chem.* 95 : 4795–4802.
- Wang, M., Bi, Y., Jin, Y., & Zheng, Z.-J. (2024). Global Incidence of Ovarian Cancer According to Histologic Subtype: A Population-Based Cancer Registry Study. *JCO Glob. Oncol.* 1–9.
- World Health Organization Expert Consultation (2004). Appropriate body mass index for Asian populations and its implications. *Lancet* 363 : 157–163.
- Zamwar, U.M., & Anjankar, A.P. (2022). Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. *Cureus* 14 : 1–7.